Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight
First author：Ma Yan, Yan
Corresponding author：WangYongjun, Du Fenghe, Fenghe
essential_information
- Person in charge：Ma Yan, Yan
- Data Sources： CHANCE
- Number of papers：OTHERS20190725
- Published time：2018-05-08
2018-05-08
Published articles
Journal：Therapeutics and Clinical Risk Management
Publication type: Original Research
IF(IF): 2.423
PMID: 29773949 Link To Pubmed Full text Download
Background And Purpose
Method
All 3,420 male participants coming from the Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events trial were divided into 3 groups based on bodyweight (<65 kg, 65-75 kg, and ≥75 kg). The stroke outcomes included stroke recurrence, combined vascular events, and bleeding events during 90 days of follow-up. The interaction of the treatment effects of DAT among patients with different bodyweight was assessed by Cox proportional hazards models.
Conclusion
DAT does not show benefit in patients with higher weight, compared with MAT. Bleeding events found in the DAT group were not more than the MAT group among patients with lower weight.
Main results
DAT is superior to mono antiplatelet therapy (MAT) for reducing stroke recurrence among patients with weight <65 kg (5.0% vs 11.7%; hazard ratio [HR], 0.41; 95% CI: 0.22-0.76) and 65-75 kg (6.7% vs 10.8%, HR, 0.62; 95% CI: 0.43-0.89). However, no significant difference was found in stroke recurrence between DAT and MAT in patients with weight ≥75 kg (9.4% vs 11.6%; HR, 0.80; 95% CI: 0.58-1.10). A significant interaction was observed between weight and antiplatelet therapy on stroke recurrence (p<0.05). Similar result was found for combined vascular events. More bleeding events were found in DAT group among patients with <65 kg (3.7% vs 2.2%), but with no significant difference.